Act Now to Preserve the PARIS Test

Your support helps ensure that patients can continue to access the PARIS Test, a functional precision oncology platform

Help preserve the PARIS Test

Every patient’s cancer is unique. The PARIS Test helps clinicians identify treatments most likely to work by testing a patient’s own tumor cells against dozens of therapies. This insight has extended lives, improved quality of life, and offered hope when standard options were exhausted.

At Risk, But Not Lost

The PARIS Test is at risk of being discontinued after being acquired in 2023. Without immediate support, the platform, CLIA-certified lab, decades of expertise and critical infrastructure could be lost, leaving patients without access to this transformative option. Rebuilding this capability later would be complex, costly, and uncertain.

Cure First is Ready to Step In

Cure First, a registered 501(c)(3) nonprofit, is prepared to take stewardship of the PARIS Test. By supporting this effort, you help:

  • Keep the lab operational and maintain CLIA certification

  • Preserve the scientific team and clinical expertise

  • Protect the high-throughput testing platform

  • Expand access to more patients and enable broader clinical adoption

The PARIS Test and CLIA-certified lab have been refined over a decade, combining functional genomics, high-throughput screening, and molecular profiling to provide actionable results for clinicians. It’s a proven platform grounded in rigorous science, peer-reviewed publications, and real-world patient outcomes. We hope you’ll join our mission to keep this tool available to patients and their healthcare providers.

Donate to Preserve the PARIS Test

Real Impact for Cancer Patients

Giving oncologists the data they need to optimize care.

The PARIS Test has already changed lives. Directly testing patients’ cancer cells has repeatedly revealed actionable insights that guide oncologists in critical care decisions: 

  • Ovarian cancer: A patient initially in hospice recovered after the test identified a targeted therapy. She went on to live several meaningful years beyond her prognosis.

  • Pancreatic cancer: A patient achieved complete remission through a PARIS-guided, HER2-directed regimen and remains alive today.

There are countless stories just like these, and we hope to be able to continue providing actionable insights to oncologists to help maximize treatment outcomes for patients and their families.

Help Bring Functional Precision Medicine to More Patients

Philanthropic support is essential to ensuring that patients continue to have access to the PARIS Test. Your contribution helps Cure First keep the lab operating, sustain the scientific team, and preserve the platform that makes functional precision medicine possible. It also supports our work to make testing more affordable, strengthen partnerships with cancer centers, and generate the evidence needed for broader insurance coverage. Every gift helps create more opportunities for patients facing difficult cancers to receive information that can guide their care.

Join the Mission